Focus: EBR Systems is a public biotech company pioneering wireless cardiac stimulation technology for heart failure treatment. The company operates at a modest commercial scale with $2M in FY2025 revenue while maintaining significant R&D investment.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
1 added, 4 removed. Backfill posture.
High-risk, high-reward opportunity for risk-tolerant professionals seeking early-stage innovation but with material concerns about company viability without immediate capital infusion.
Help build intelligence for EBR Systems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from EBR Systems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles